- Home
- DVA vs CHE Comparison
DVA vs CHE Comparison
Compare DVA & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- CHE
- Stock Information
- Founded
- DVA 1994
- CHE 1970
- Country
- DVA United States
- CHE United States
- Employees
- DVA N/A
- CHE N/A
- Industry
- DVA Misc Health and Biotechnology Services
- CHE Medical/Nursing Services
- Sector
- DVA Health Care
- CHE Health Care
- Exchange
- DVA Nasdaq
- CHE Nasdaq
- Market Cap
- DVA 9.4B
- CHE 8.0B
- IPO Year
- DVA 1995
- CHE N/A
- Fundamental
- Price
- DVA $126.99
- CHE $443.49
- Analyst Decision
- DVA Hold
- CHE Strong Buy
- Analyst Count
- DVA 3
- CHE 4
- Target Price
- DVA $151.00
- CHE $578.50
- AVG Volume (30 Days)
- DVA 634.2K
- CHE 183.5K
- Earning Date
- DVA 10-29-2025
- CHE 10-28-2025
- Dividend Yield
- DVA N/A
- CHE 0.54%
- EPS Growth
- DVA 8.72
- CHE N/A
- EPS
- DVA 10.20
- CHE 19.48
- Revenue
- DVA $13,161,328,000.00
- CHE $2,511,915,000.00
- Revenue This Year
- DVA $5.96
- CHE $5.91
- Revenue Next Year
- DVA $3.54
- CHE $6.72
- P/E Ratio
- DVA $12.35
- CHE $22.62
- Revenue Growth
- DVA 5.09
- CHE 7.55
- 52 Week Low
- DVA $122.93
- CHE $408.42
- 52 Week High
- DVA $179.60
- CHE $623.61
- Technical
- Relative Strength Index (RSI)
- DVA 43.91
- CHE 46.64
- Support Level
- DVA $124.60
- CHE $429.77
- Resistance Level
- DVA $127.92
- CHE $439.62
- Average True Range (ATR)
- DVA 2.70
- CHE 8.25
- MACD
- DVA -0.05
- CHE 0.33
- Stochastic Oscillator
- DVA 33.99
- CHE 50.32
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
About CHE Chemed Corp
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.